Search

The article discusses research on the safety, efficacy and tolerability of a novel potent epithelial sodium channel (ENaC) blocker in patients with symptoms of mild-to-moderate dry eye disease compared with placebo. The study examined the inhibition of ENaC on the ocular surface in dry eye patients and analyzed the tear-P-321 pharmacokinetic profile following drug administration and the adverse events of the drug.

The article discusses the harmful errors in preparing dosing flecainide suspension which is an oral class 1c antiarrhythmic drug for treating atrial fibrillation or supraventricular tachycardia. Topics covered include details relating to a case involving flecainide suspension-related error reported to the Institute for Safe Medication Practices (ISMP) in 2007, recommendations for reducing the risk of errors, and the need for including the concentration in the pharmacy label.

The article discusses a study which examined concentrations of topical ocular hydrating agent P-321 in patients with mild to moderate dry eye disease. Topics covered include the function of P-321 as an epithelial sodium channel blocker, the explanation given by professor Richard C. Boucher Jr. on the way P-321 addresses dryness and the possible administration of P-321 with a once-a-day regimen.